Plexxikon Inc.

Cv Therapeutics, Inc.

Daiichi Sankyo Company, Limited

Afferent Pharmaceuticals, Inc.

Hoffmann-la Roche Inc.

Gilead Palo Alto, Inc.

Gilead Sciences, Inc.

Other

Merck Sharp + Dohme Corp.

Opna Bio Sa

Cv Theapeutics, Inc.

F. Hoffmann-la Roche Ag

Daiichi Sankyo, Inc.

Prabha N Ibrahim

Jiazhong Zhang

Chao Zhang

Wayne Spevak

Jeff A Zablocki

Dean R Artis

Guoxian Wu

Venkata Poornapragnacharyulu Palle

Elfatih O Elzein

Songyuan Shi

Jack Lin

Hanna Cho

Marika Nespi

Ryan Bremer

Ying Zhang

Vaibhav Varkhedkar

Todd Ewing

Gary Conard Visor

Xiaofen Li

Thao Perry

Dengming Xiao

Kevin D Shenk

Klaus-Peter Hirth

Gideon Bollag

Rebecca Zuckerman

Clarence R Hurt

Rao V Kalla

Hongyao Zhu

Ronald Charles Hawley

Shumeye Mamo

Anthony P Ford

Shenghua Shi

Ben Powell

Katrina Chan

Brian L West

Robert H Jiang

Kenneth S Rehder

Heike I Krupka

Yan Ma

Gaston G Habets

Yong-Liang Zhu

Phuongly Pham

Weiru Wang

John Buell

Christopher F Morrison

Hamid Rezaei

Joel R Gever

James Tsai

Shinji Matsuura

Michael V Milburn

Jeffrey Yung Wu

Samuel J Gillette

Masayoshi Jin

James Arnold

Jianming Tsai

Richard M Lawn

Michael G Campbell

Tim Marquart

Ralph Diodone

Tomoari Kamo

Hiroshi Yamakose

Sam Gillette

Byunghun Lee

Paul Lin

Navnit Hargovindas Shah

Dipen Desai

Harpreet Kaur Sandhu

Brent K Blackburn

Zenaida Go

Hans-Juergen Mair

Steven A Smith

Elfaith O Elzein

Nicole Wyttenbach

Bruce England

Abhinav Kumar

Arvinder Dhalla

Venkata P Palle

Raman Iyer

Johannes Pudewell

Frank Wierschem

Zuojun Guo

Shan-Ming Kuang

Richard L Mackman

Yoshihisa Suzuki

Elizabeth A Burton

Ken Dong

Luiz Belardenelli

Stephan Lauper

Dmitry Koltun

Steven R Schow

Robert T Lum

Urs Schwitter

Aaron Edward Albers

Michael M Wick

Hannah Powers

Cheri Lynn Blum

Yong Zhou

Baoshu Zhao

Karsten Fähnrich

Yoshisa Suzuki

Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Heterocyclic compounds and uses thereof

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Substituted pyrazole-pyrimidines, variants thereof, and uses therefore

Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.

Crystalline salts and polymorphs of a P2X3 antagonist

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Pyrimidines and variants thereof, and uses therefor

Provided are solid dispersions of Compound I having the formula: wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.

Formulations of a compound modulating kinases

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders. 

Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.

The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

The present disclosure provides processes for the preparation of a compound of formula I: or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Synthesis of a compound that modulates kinases

Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.

Solid forms of a compound for modulating kinases

Growing community of inventors

Mountain View, CA, United States of America

Prabha N Ibrahim